Hemispherx Biopharma

Latest news

• AIM ImmunoTech to Evaluate Ampligen in Clinical Study for the Treatment of Post-COVID Conditions
  12 October 2022
• Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen Produced 100% Survival Rate in Rodents with 100% Mortality in Placebo
  9 February 2015
• Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen Enlarged by Howard University Research
  9 December 2014
• Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen New Drug Application for Chronic Fatigue Syndrome
  5 February 2013
• FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome
  27 December 2012
• Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
  23 October 2012
• Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen for Chronic Fatigue Syndrome
  24 September 2012
• FDA Accepts Complete Response Submission Regarding the Ampligen New Drug Application for Chronic Fatigue Syndrome
  14 August 2012
• Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen New Drug Application for Chronic Fatigue Syndrome
  1 August 2012
• Hemispherx Biopharma Reaches Agreement With FDA on Specific Steps to Achieve Complete NDA on Proposed CFS Treatment Ampligen
  7 March 2008

Drugs Associated with Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.